The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Time from prior chemotherapy (TFPC) as a prognostic factor in advanced urothelial carcinoma (UC) receiving second-line systemic therapy.
Gregory Russell Pond
No relevant relationships to disclose
Guru Sonpavde
No relevant relationships to disclose
Toni K. Choueiri
No relevant relationships to disclose
Angela Q. Qu
No relevant relationships to disclose
David J. Vaughn
No relevant relationships to disclose
Ronan Fougeray
Employment or Leadership Position - Pierre Fabre Medicament
Guenter Niegisch
No relevant relationships to disclose
Peter Albers
No relevant relationships to disclose
Yu-Ning Wong
Consultant or Advisory Role - Bristol-Myers Squibb (U)
Research Funding - Bristol-Myers Squibb
Yoo-Joung Ko
Research Funding - Abraxis BioScience
Srikala S. Sridhar
Research Funding - Abraxis BioScience
Matt D. Galsky
No relevant relationships to disclose
Daniel Peter Petrylak
No relevant relationships to disclose
Tomasz M. Beer
No relevant relationships to disclose
Walter Michael Stadler
Research Funding - Boehringer Ingelheim
Peter H. O'Donnell
No relevant relationships to disclose
Cora N. Sternberg
No relevant relationships to disclose
Jonathan E. Rosenberg
No relevant relationships to disclose
Joaquim Bellmunt Molins
Research Funding - Pierre Fabre Medicament